The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology

Cells. 2022 Oct 18;11(20):3282. doi: 10.3390/cells11203282.

Abstract

Right ventricular failure (RVF) is the most important prognostic factor for morbidity and mortality in pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH) caused by left heart diseases. However, right ventricle (RV) remodeling is understudied and not targeted by specific therapies. This can be partly explained by the lack of basic knowledge of RV remodeling. Since the physiology and hemodynamic function of the RV differ from those of the left ventricle (LV), the mechanisms of LV dysfunction cannot be generalized to that of the RV, albeit a knowledge of these being helpful to understanding RV remodeling and dysfunction. Store-operated Ca2+ entry (SOCE) has recently emerged to participate in the LV cardiomyocyte Ca2+ homeostasis and as a critical player in Ca2+ mishandling in a pathological context. In this paper, we highlight the current knowledge on the SOCE contribution to the LV and RV dysfunctions, as SOCE molecules are present in both compartments. he relative lack of studies on RV dysfunction indicates the necessity of further investigations, a significant challenge over the coming years.

Keywords: Orai1/3; SOCE; SOCs; STIM1/2; TRPCs; calcium signaling; left and right heart failure; left and right hypertrophy; pulmonary hypertension.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Heart Ventricles / pathology
  • Humans
  • Hypertension, Pulmonary*
  • Male
  • Myocytes, Cardiac / pathology
  • Ventricular Dysfunction, Right*
  • Ventricular Remodeling / physiology

Grants and funding

This study was supported by grants from the French National Institute for Health and Medical Research (INSERM), the Université Paris-Saclay, the Marie Lannelongue Hospital. Fabrice Antigny received funding from the National Funding Agency for Research: ANR-18-CE14-0023 and funding from the French association “Fédération Française de Cardiologie”). Jean-Pierre Benitah received funding from the ANR: ANR-19-CE14-0031-1. RL was a recipient of the CSC (Chinese Scholarship Council) doctoral fellowship. Antoine Beauvais is supported by the French association “Fondation du Souffle”. Bastien Masson is supported by the Therapeutic Innovation Doctoral School (ED569).